FDA Approves First-Ever Treatment for Acquired Hypothalamic Obesity – IMCIVREE Now Available
Rhythm Pharmaceuticals receives FDA approval for IMCIVREE (setmelanotide) — the first and only treatment for acquired hypothalamic obesity.
/ 5 items
#RYTM↓
Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost
Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.
Promising New Treatment Shows Early Success for Prader-Willi Syndrome
Rhythm Pharmaceuticals (RYTM) announces positive results from Phase 2 trial of setmelanotide for Prader-Willi syndrome, showing BMI reduction and decreased hunger in patients.
FDA Extends Review for Rhythm’s Obesity Drug Imcivree to March 2026
Rhythm Pharmaceuticals announced that the FDA has extended the review of its obesity drug Imcivree for acquired hypothalamic obesity by three months, moving the decision date to March 20, 2026.
Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.